GLP-1 Receptor Agonist Market Report 2026

GLP-1 Receptor Agonist Market Overview

• GLP-1 Receptor Agonist market size has reached to $14.09 billion in 2025 • Expected to grow to $18.32 billion in 2030 at a compound annual growth rate (CAGR) of 5.4% • Growth Driver: Surging Diabetes Cases Fuel Growth In Glp-1 Receptor Agonist Market • Market Trend: Sustained-Release Glp-1 Receptor Agonists Are Gaining Popularity • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under GLP-1 Receptor Agonist Market?

A GLP-1 receptor agonist is a type of medication that stimulates insulin release at high blood glucose levels and suppresses glucagon secretion under low blood glucose conditions. They are used to treat type 2 diabetes mellitus. The main drug class of GLP-1 receptor agonist is liraglutide, dulaglutide, lixisenatide, and others. Liraglutide is a GLP-1 receptor agonist that acts by helping the pancreas to release the right amount of insulin when blood sugar levels are high. The route of administration involved is parenteral, and oral which are used by hospitals, surgical clinics, and others.

What Is The GLP-1 Receptor Agonist Market Growth Forecast?

The glp-1 receptor agonist market size is expected to see strong growth in the next few years. It will grow to $18.32 billion in 2030 at a compound annual growth rate (CAGR) of 5.4%. The growth in the forecast period can be attributed to growing obesity population, expanding approval for cardiovascular risk reduction, innovation in oral and combination therapies, increased penetration in emerging markets, rising patient preference for weight loss benefits. Major trends in the forecast period include expansion of glp-1 therapies beyond diabetes, rising demand for long-acting and once-weekly formulations, growth of oral glp-1 receptor agonists, increasing focus on weight management indications, strategic partnerships and licensing agreements.

Global GLP-1 Receptor Agonist Market Segmentation

1) By Drug Class: Exenatide, Liraglutide, Dulaglutide, Lixisenatide, Other Drugs 2) By Route Of Administration: Parenteral, Oral 3) By End Users: Hospitals, Surgical Clinics, Other Users

What Is The Driver Of The GLP-1 Receptor Agonist Market?

The rising prevalence of diabetes is expected to propel the GLP-1 receptor agonist market going forward. Diabetes is a chronic illness that develops when the pancreas either produces insufficient amounts of insulin or when the body cannot properly utilize the insulin that it does. High blood sugar is a symptom of the metabolic disorder diabetes mellitus. GLP-1 receptor agonist is used in diabetes to stimulate the body to produce more insulin, which helps to lower blood sugar levels, so the rising prevalence of diabetes will propel the market growth. For instance, in March 2024, according to the Office for Health Improvement and Disparities, a UK-based government department, between March 2022 and March 2023, the percentage of individuals with type 1 diabetes receiving all eight recommended care processes increased by 22%, and for type 2 diabetes, it increased by 21%, while the percentage achieving target HbA1c levels rose to 37.9%. Therefore, the rising prevalence of diabetes is driving the GLP-1 receptor agonist industry.

Key Players In The Global GLP-1 Receptor Agonist Market

Major companies operating in the glp-1 receptor agonist market are Novo Nordisk A/S, Sanofi SA, Eli Lilly and Company, AstraZeneca Inc., Boehringer Ingelheim International GmbH, Hanmi Pharm Co. Ltd., Pfizer Inc., Amgen Inc., Innovent Biologics Inc., Jiangsu Hengrui Medicine Co., Sun Pharmaceuticals Industries Ltd., PegBio Co. Ltd., Zealand Pharma A/S, Bristol-Myers Squibb Company, Chongqing Lummy Pharmaceutical Co. Ltd., Daiichi Sankyo Company Limited, Dong-A ST Co. Ltd., Eisai Co. Ltd., HanAll Biopharma Co. Ltd., Ipsen SA, Johnson & Johnson, Merck & Co. Inc., Novartis AG.

Global GLP-1 Receptor Agonist Market Trends and Insights

Major companies operating in the GLP-1 receptor agonist market are focused on developing sustained-release GLP-1 receptor agonists to gain a competitive edge in the market. Sustained-release GLP-1 receptor agonists (GLP-1RAs) are a type of medication that slowly releases GLP-1RA into the bloodstream over time, which allows for longer-lasting effects and less frequent injections compared to traditional GLP-1RAs. For instance, in April 2023, Mitsubishi Tanabe Pharma Corporation, a Japan-based pharmaceuticals company, launched Mounjaro 2.5 mg or 5 mg Ateos. It is the world's first sustained-release GIP/GLP-1 receptor agonist for the treatment of type 2 diabetes that activates both the GLP-1 and GIP receptors. The GLP-1 receptor is involved in regulating blood sugar levels, while the GIP receptor is involved in stimulating insulin secretion and reducing appetite.

What Are Latest Mergers And Acquisitions In The GLP-1 Receptor Agonist Market?

In July 2024, Roche, a Swiss-based pharmaceuticals company, acquired Carmot Therapeutics for US$ 2.7 billion (with up to US$ 400 million in additional milestone payments). With this acquisition, Roche aimed to strengthen its metabolic disease franchise by gaining access to Carmot’s advanced portfolio, particularly a phase-2-ready dual GLP-1/GIP receptor agonist, thereby enhancing its competitive position in both obesity and diabetes markets. Carmot Therapeutics is a U.S.-based biotech company focused on developing incretin-based therapies, including CT-388 (a weekly injectable dual GLP-1/GIP agonist), an oral small-molecule GLP-1 agonist (CT-996), and another injectable GLP-1/GIP candidate (CT-868).

Regional Insights

North America was the largest region in the GLP-1 receptor agonist market in 2025. Asia-Pacific is expected to be the fastest-growing region in the GLP-1 receptor agonist market report during the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the GLP-1 Receptor Agonist Market?

The GLP-1 receptor agonist market consists of sales of dulaglutide, bydureon b-cise, exenatide, and semaglutide. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the GLP-1 Receptor Agonist Market Report 2026?

The glp-1 receptor agonist market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the glp-1 receptor agonist industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.